echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > First in China, approved clinical application of Lizhu pharmaceutical's monoclonal antibody IL-17A / F

    First in China, approved clinical application of Lizhu pharmaceutical's monoclonal antibody IL-17A / F

    • Last Update: 2020-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 20, Lizhu pharmaceutical released the enterprise announcement

    Recently, Zhuhai Lizhu mAb Biotechnology Co., Ltd

    (hereinafter referred to as "Lizhu mAb"), a holding subsidiary of Lizhu Pharmaceutical Group Co., Ltd., and Beijing xinkanghe Biomedical Technology Co., Ltd

    (hereinafter referred to as "xinkanghe biology") jointly declared the "recombinant anti-human IL-17A / F humanized monoclonal antibody injection" ”The clinical trial application was approved by the State Drug Administration (hereinafter referred to as "the drug administration")

    "Recombinant anti-human IL-17A / F humanized monoclonal antibody injection" has been developed for 4 years, and the clinical trial application has been approved on February 19, 2020 (acceptance No.: cxsl1900130)

    The recombinant anti-human IL-17A / F humanized monoclonal antibody injection can simultaneously target the homologous dimer il-17a-a and il-17f-f, as well as the heterodimer il-17a-f

    IL-17A and IL-17F exist in the form of homologous dimer il-17a-a and il-17f-f, and heterodimer il-17a-f

    They are mainly produced by T helper Th17 subsets, but also by other T cells, neutrophils and mast cells

    These dimers, acting on receptors il-17ra and il-17rc, can promote the expression of other proinflammatory cytokines (such as IL-6, TNF α, IL-1 β, IL-20 family cytokines, GM-CSF) and effector proteins, and further lead to the activation of neutrophils and macrophages, epithelial cells and fibroblasts, which play an important role in the pathophysiology of many autoimmune diseases

    As of the disclosure date of the announcement, the cumulative R & D investment of "recombinant anti-human IL-17A / F humanized monoclonal antibody injection" of Lizhu pharmaceutical has been about 39.2376 million yuan

    In addition, according to the announcement, for IL-17A target: at present, two domestic imported products have been approved for listing in 2019, and five other domestic enterprises have been approved for clinical trials, all of which are in early clinical trials

    In addition, for IL-17A / F target: at present, there is no such target product in the world, and no other company in China has applied for clinical application

    37
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.